Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Completion of phase Ia study of FOR-6219 for endometriosis paves way for phase Ib

March 7, 2019

Bifunctional TFR1 ligand-peptides as erythroblast-targeted gene therapy for erythroid disorders

March 7, 2019

Phase III study of givosiran in acute hepatic porphyria meets primary endpoint

March 6, 2019

Zealand Pharma begins dosing in phase III trial of dasiglucagon in congenital hyperinsulinism

March 6, 2019

Janssen Pharmaceutica discloses prostanoid EP3 receptor antagonists

March 6, 2019

Newly identified pathway provides fat for macrophages

March 6, 2019

Ascendis Pharma presents results from phase III heiGHt trial for TransCon hGH

March 5, 2019

Arrowhead opens enrollment in phase I study of ARO-APOC3

March 4, 2019

Double dose of suicide genes increases beta-cell safety, efficacy

Feb. 28, 2019

Northwestern University presents beta-glucocerebrosidase activators

Feb. 27, 2019

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...